Asosiy kontentga oʻtish
AkademIndex

Xizmatlar

← Ishga qaytish

Ushbu ish iqtibos qilgan ishlar

321 ta ish

Ish: COVID-19 Vaccines - Current State and Perspectives

  1. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

    Stephen A. Lauer, Kyra H. Grantz, Qifang Bi +6

    MaqolaOchiq kirish202010 iqtibos
    ABI

  2. Profiling of the most reliable mutations from sequenced SARS-CoV-2 genomes scattered in Uzbekistan

    Mirzakamol S. Ayubov, Zabardast T. Buriev, Mukhammadjon K. Mirzakhmedov +5

    MaqolaOchiq kirishSARS-CoV-2 and COVID-19 ResearchPLoS ONE202210 iqtibos
    ABI

  3. A new coronavirus associated with human respiratory disease in China

    Fan Wu, Zhao Su, Bin Yu +16

    Maqola20209 iqtibos
    ABI

  4. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

    Lianpan Dai, Tianyi Zheng, Kun Xu +18

    MaqolaOchiq kirish20208 iqtibos
    ABI

  5. Sarlavhasiz

    Boshqa8 iqtibos
    ABI

  6. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

    Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin +26

    Maqola20208 iqtibos
    ABI

  7. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

    Victor M. Corman, Olfert Landt, Marco Kaiser +21

    MaqolaOchiq kirish20207 iqtibos
    ABI

  8. Genome sequence diversity of SARS-CoV-2 obtained from clinical samples in Uzbekistan

    А. А. Абдуллаев, Abrorjon Abdurakhimov, Zebinisa Mirakbarova +6

    MaqolaOchiq kirishSARS-CoV-2 and COVID-19 ResearchPLoS ONE20226 iqtibos
    ABI

  9. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

    Shilong Yang, Yan Li, Lianpan Dai +26

    MaqolaOchiq kirish20216 iqtibos
    ABI

  10. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

    Lindsey R. Baden, Hana M. El Sahly, Brandon Essink +34

    Maqola20206 iqtibos
    ABI

  11. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

    Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov +28

    Maqola20216 iqtibos
    ABI

  12. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

    Daniel Wrapp, Nianshuang Wang, Kizzmekia S. Corbett +5

    MaqolaOchiq kirish20205 iqtibos
    ABI

  13. Covid‐19 vaccines and variants of concern: A review

    Ikbel Hadj Hassine

    Sharh maqolaOchiq kirish20215 iqtibos
    ABI

  14. Epidemiology of COVID-19 Among Children in China

    Yuanyuan Dong, Xi Mo, Yabin Hu +4

    Maqola20205 iqtibos
    ABI

  15. Determinants of disparities between perceived and physiological risk of falling among elderly people: cohort study.

    Kim Delbaere, Jacqueline Close, Henry Brodaty +2

    Maqola20105 iqtibos
    ABI

  16. Vaccine hesitancy: Definition, scope and determinants

    Noni E. MacDonald

    MaqolaOchiq kirish20154 iqtibos
    ABI

  17. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

    Jun Lan, Jiwan Ge, Jinfang Yu +8

    MaqolaOchiq kirish20204 iqtibos
    ABI

  18. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

    Jerald Sadoff, Glenda Gray, An Vandebosch +27

    Maqola20214 iqtibos
    ABI

  19. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

    Saghi Nooraei, Howra Bahrulolum, Zakieh Sadat Hoseini +4

    Sharh maqolaOchiq kirish20213 iqtibos
    ABI

  20. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

    Ruiyun Li, Sen Pei, Бин Чэн +4

    Maqola20203 iqtibos
    ABI

  21. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

    Luca Piccoli, Young‐Jun Park, M. Alejandra Tortorici +47

    Maqola20203 iqtibos
    ABI

  22. Genotype and phenotype of COVID-19: Their roles in pathogenesis

    Leila Mousavizadeh, Sorayya Ghasemi

    Sharh maqola20203 iqtibos
    ABI

  23. Circular RNA: A new star of noncoding RNAs

    Shibin Qu, Xisheng Yang, Xiaolei Li +6

    Sharh maqola20153 iqtibos
    ABI

  24. Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant

    Xin Zhao, Dedong Li, Wenjing Ruan +9

    Boshqa20223 iqtibos
    ABI

  25. Vaccine development and therapeutic design for 2019‐nCoV/SARS‐CoV‐2: Challenges and chances

    Mahnaz Ghaebi, Abdolreza Osali, Hamed Valizadeh +2

    Sharh maqola20203 iqtibos
    ABI